MYRICX
Live / Applied — Non-final action written — not yet mailed (as of 03 Mar 2026)
What this means for you
Not registered yet, but its 06 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79444386
- Mark type
- Stylized text
- Filed
- 06 Aug 2025
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of proliferative human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging.
- Class 042 — Scientific and technological services: Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development, testing and commercialisation of pharmaceuticals and biotechnological preparations (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); development, testing and commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors (term considered too vague by the International Bureau pursuant to Rule 13 (2) (b) of the Regulations); consultancy, advisory and information services relating to the aforesaid services.
Owner
Prosecution history
- 26 Mar 2026 — CORRECTION TRANSACTION RECEIVED FROM IB
- 04 Mar 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 03 Mar 2026 — NON-FINAL ACTION WRITTEN
- 28 Feb 2026 — ASSIGNED TO EXAMINER
- 27 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 27 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 26 Feb 2026 — SN ASSIGNED FOR SECT 66A APPL FROM IB